Miltefosine

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.

INDICATIONS

FDA

  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
  • Miltefosine no longer needs to be obtained through the CDC.

NON-FDA APPROVED USES

  • Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved